Evaluation of histidine-rich glycoprotein tissue RNA and serum protein as novel markers for breast cancer

Medical Oncology

Volumn 31, Issue 4, 2014, Pages

  Matboli, Marwa ^a   Eissa, Sanaa ^a   Said, Hebatallah ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Bioinformatics; Breast carcinoma; ELISA; Histidine rich glycoprotein; Serum markers

Indexed keywords

GLYCOPROTEIN; HISTIDINE RICH GLYCOPROTEIN; ORAL CONTRACEPTIVE AGENT; PLASMA PROTEIN; RNA; UNCLASSIFIED DRUG; HISTIDINE RICH PROTEINS; HISTIDINE-RICH PROTEINS; PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOINFORMATICS; BREAST BIOPSY; BREAST CANCER; BREAST FIBROADENOMA; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PILOT STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ALGORITHM; BIOLOGY; BLOOD; BREAST TUMOR; CHEMISTRY; FIBROADENOMA; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; METABOLISM; METHODOLOGY; MIDDLE AGED; PROGNOSIS; PROTEOMICS; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; ALGORITHMS; BREAST NEOPLASMS; COMPUTATIONAL BIOLOGY; FEMALE; FIBROADENOMA; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; PROTEINS; PROTEOMICS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84894265710     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0897-4     Document Type: Article

References (31)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Cancer incidence and mortality worldwide: IARC cancer base no. 10. Lyon: International Agency for Research on Cancer; 2012.
2. Misek DE, Kim EH. Protein biomarkers for the early detection of breast cancer. Int J Proteomics. 2011;2011:343582.
3. Cecchini RS, Costantino JP, Cauley JA, Cronin WM. Body mass index and the risk for developing invasive breast cancer among high-risk women in NSABP P-1 and STAR breast cancer prevention trials. Cancer Prev Res. 2012;5(4):583-92.
4. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70. doi: 10.1038/nature11412.
5. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature. 2000;406(6797):747-52.
6. Slamon D, Leyland-Jones B, Shak S, et al. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Presented at: 34th annual meeting of the American Society of Clinical Oncology; May 16-19, 1998. Los Angeles, CA. Abstract 377.
7. Herceptin [prescribing information]. South San Francisco, CA: Genentech, Inc; 2010.
8. Schaub NP, Jones KJ, Nyalwidhe JO, Cazares LH, Karbassi ID, Semmes OJ. Serum proteomic biomarker discovery reflective of stage and obesity in breast cancer patients. J Am Coll Surg. 2009;208(5):970-8.
9. Thulin A. Role of histidine-rich glycoprotein in angiogenesis and tumor growth. Acta Universtatis Upsaliensis. Digital Comprehensive summaries of Uppsala Dissertation from faculty of medicine 505.63 pp. Uppsala; 2009. ISBN-978-91-554-7674-8.
10. Jain S, Zuka M, Liu J, et al. Platelet glycoprotein Ib alpha supports experimental lung metastasis. Proc Natl Acad Sci USA. 2010;104(21):9024-8.
11. Carey LA. Molecular intrinsic subtypes of breast cancer. In Hayes DF, Dizon DS, editors. Up to date. Waltham, MA: Up To Date; 2012.
12. Pinder SE, Elston CW, Ellis IO. In Invasive carcinoma: usual histological types. 3rd ed. In: Elston CW, Ellis IO, editors. The breast. Edinburgh: Churchill Livingstone; 1998. p. 283-337.
13. Sobin L, Gospodarowicz M, Wittekind C, editors. TNM classification of malignant tumors. 7th ed. Hoboken, NJ: Wiley; 2009.
14. World Health Organization. International histological classification of tumours. 2nd ed. Geneva: World Health Organization, 1969-1981. Berlin: Springer; 1988. Present.
15. Hummon AB, Lim SR, Difilippantonio MJ, Ried T. Isolation and solubilization of proteins after TRIzol® extraction of RNA and DNA from patient material following prolonged storage. Biotech J. 2007;42:467-72.
16. Koide T, Foster D, Yoshitake S, Davie EW. Amino acid sequence of human histidine rich glycoprotein derived from the nucleotide sequence of its cDNA. Biochem J. 1986;25:2220-5.
17. Sabbatini ARM, Battolla MB, Martini PE, Ranieri-Raggi DM, Moir AJG, Raggi A. Evidence that muscle cells do not express the histidine-rich glycoprotein associated with AMP deaminase but can internalise the plasma protein. Eur J Histochem. 2011;55(1):e6. doi: 10.4081/ejh.2011.e6.
18. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC. Urine detection of survivin and diagnosis of breast cancer. JAMA J. 2001;285(3):324-8.
19. Zweig MH, Campbell G. Receiver operating characteristic (ROC) Plots, a fundamental evaluation tool in clinical medicine. Clin Chem J. 1993;39(4):561-77.
20. Ringner M, Fredlund E, Hakkinen J, Borg A, Staaf J. GOBO: gene expression-based outcome for breast cancer online. PLoS One J. 2011;6:e17911.
21. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nat J. 2000;406:747-52.
22. Eissa S, Swellam M, Ismail M, Hamdy M, Mokhtar N. Emerging role of p53, bcl-2 and telomerase activity in Egyptian breast cancer patients. IUBMB Life J. 2004;56(8):483-90.
23. Thulin A, Ringvall M, Dimberg A, et al. Activated platelets provide a functional microenvironment for the antiangiogenic fragment of histidine-rich glycoprotein. Mol Cancer Res J. 2009;7(11):1792-802.
24. Klenotic PA, Huang P, Palomo J. Histidine-rich glycoprotein modulates the anti-angiogenic effects of vasculostatin. Am J Pathol. 2010;176(4):2039-50.
25. Saigo K, Yoshida A, Sugano W, Ryo R, Yamaguchi N. Histidine-rich glycoprotein in blood during inflammation, surgical operation or hemodialysis. Rinsho Ketsueki. 1990;31(12):1914-9.
26. Menga R, Gormleya M, Vadiraja B, Rosenbergc BA, Quonga AA. Low abundance protein enrichment for discovery of candidate plasma protein biomarkers for early detection of breast cancer. J Proteomics. 2011;1(75):366-74.
27. Reeves GK, Beral V, Green J, Gathani T, Bull D. Hormonal therapy for menopause and breast cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol J. 2006;7:910-8.
28. DeMaat MPM, Kameling SWA, Kluft C. The sensitivity and specificity of some clotting rate and immunological fibrinogen assays for high, low and low molecular weight forms of fibrinogen. In: DeMaat MPM, editor. Regulation and modulation of the plasma fibrinogen level. Rotterdam: University of Rotterdam. Thesis; 1995. pp. 47-59.
29. Rohleder N, Wolf JM, Piel M, Kirschbaum C. Impact of oral contraceptive use on glucocorticoid sensitivity of pro-inflammatory cytokine production after psychosocial stress. Psychoneuroendocrinology. 2003;28(3):261-73.
30. Schwanhausser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, Chen W, Selbach M. Global quantification of mammalian gene expression control. Nature. 2011;473(7347):337-42.
31. Shebl F, Pinto LA, Garcia-Pineres A, Lempicki R, Williams M, Harro C, Hildesheim A. Comparison of mRNA and protein measures of cytokines following vaccination with human papillomavirus-16 L1 virus-like particles. Cancer Epidemiol Biomarkers Prev. 2010;19(4):978-81.